Pertussis Vaccine Market Size, Share, Growth, and Industry Analysis, By Type (Acellular Vaccines, Whole-cell Vaccines), By Application (12 Months Below, 12 Months Above), Regional Insights and Forecast to 2035

Pertussis Vaccine Market Overview

The global Pertussis Vaccine Market size estimated at USD 5748.87 million in 2026 and is projected to reach USD 7187.66 million by 2035, growing at a CAGR of 2.51% from 2026 to 2035.

The Pertussis Vaccine Market is supported by large-scale childhood immunization programs, booster vaccination, maternal vaccination, and combination-vaccine use. Pertussis remains a vaccine-preventable respiratory infection with periodic outbreaks even in countries reporting childhood vaccine coverage above 90%. Globally, about 84% of infants receive three doses of diphtheria-tetanus-pertussis-containing vaccine, leaving roughly 16% without complete primary protection. Acellular vaccines dominate many high-income immunization programs, while whole-cell formulations remain important across lower-cost public vaccination systems. 

In the USA, pertussis vaccination is built around DTaP for young children and Tdap for older children, adolescents, adults, and pregnant women. The standard childhood schedule contains 5 DTaP doses, generally administered at 2, 4, 6, 15–18 months, and 4–6 years. Adolescents routinely receive 1 Tdap dose at 11–12 years. Tdap is also recommended during every pregnancy, preferably between 27 and 36 weeks, helping transfer protective antibodies to newborns. Childhood DTaP coverage exceeds 90% for several early-dose measures, although later-dose completion and geographic coverage gaps continue influencing Pertussis Vaccine Market demand.

Key Findings

• Key Market Driver: Global three-dose diphtheria-tetanus-pertussis vaccine coverage is approximately 84%, while coverage exceeds 90% across several developed immunization systems, sustaining recurring procurement and replacement demand.
• Major Market Restraint: Approximately 16% of infants globally remain outside complete three-dose diphtheria-tetanus-pertussis coverage, while vaccination gaps exceeding 20% persist across several underserved populations and health systems.
• Emerging Trends: Maternal Tdap vaccination can reduce pertussis occurrence among infants by more than 75%, while protection against severe infant outcomes can exceed 90%, supporting pregnancy-focused immunization strategies.
• Regional Leadership: North America represents an estimated 35% of commercial pertussis vaccine demand, Europe accounts for approximately 29%, Asia-Pacific represents 28%, and Middle East & Africa holds around 8%.
• Competitive Landscape: Leading multinational vaccine manufacturers collectively represent more than 55% of the accessible branded combination-vaccine segment, supported by established DTaP and Tdap portfolios and extensive government procurement relationships.
• Market Segmentation: Acellular vaccines represent approximately 68% of commercially significant pertussis vaccine demand, while whole-cell vaccines account for nearly 32%, supported mainly by cost-sensitive national immunization programs.
• Recent Development: More than 70% of advanced pertussis vaccine development activity emphasizes improved durability, combination formulations, maternal protection, or next-generation antigen technologies designed to strengthen protection beyond existing products.

Pertussis Vaccine Market Latest Trends

Pertussis Vaccine Market Trends increasingly center on maternal immunization, adolescent boosters, combination products, and improved duration of protection. Primary childhood vaccine coverage reaches more than 90% in numerous developed economies, yet immunity can decline several years after vaccination. This creates continued demand for booster doses and improved formulations capable of maintaining stronger immune responses.

Another important Pertussis Vaccine Industry trend is the shift toward acellular products in higher-income countries because of their generally lower reactogenicity. Acellular formulations account for an estimated 68% of commercially important demand, while whole-cell vaccines maintain about 32%, particularly in public programs prioritizing affordability and broad population coverage.

Pertussis Vaccine Market Dynamics

DRIVER

"Expanding routine childhood and maternal immunization coverage"

The strongest Pertussis Vaccine Market Growth driver is the continuing need for routine infant vaccination combined with boosters and maternal immunization. Approximately 84% of infants globally receive three doses of a diphtheria-tetanus-pertussis-containing vaccine, making pertussis-containing products one of the most widely administered vaccine categories. Many high-income countries maintain coverage above 90%, creating a stable replacement cycle because every new birth cohort requires primary vaccination. The USA schedule includes 5 DTaP doses before or during early school age, followed by a routine Tdap booster at 11–12 years. Pregnancy creates another recurring demand pool because Tdap is recommended during every pregnancy, with administration commonly targeted between 27 and 36 weeks. Maternal vaccination can prevent more than 75% of pertussis cases among very young infants and provides protection exceeding 90% against severe outcomes in several assessments. 

RESTRAINTS

"Waning immunity and uneven vaccination completion"

A major restraint in the Pertussis Vaccine Market is declining protection after vaccination combined with incomplete coverage among specific populations. Although primary vaccination produces substantial protection, immunity from acellular pertussis vaccines can decrease over several years, requiring additional booster strategies. Global three-dose coverage of approximately 84% also means around 16% of infants do not receive complete primary vaccination. Coverage differences can become considerably larger within low-income areas, conflict-affected locations, remote communities, and populations with limited access to routine healthcare. Even where early DTaP coverage exceeds 90%, completion of later childhood doses can be lower. Vaccine hesitancy further affects uptake, particularly where perceived disease risk falls after successful immunization programs. These factors complicate Pertussis Vaccine Market Forecast models because high national coverage can coexist with local immunity gaps capable of supporting outbreaks. 

OPPORTUNITY

"Expansion of maternal vaccination and next-generation pertussis vaccines"

Maternal immunization represents one of the largest Pertussis Vaccine Market Opportunities because newborns face their highest vulnerability before completing the primary infant vaccine series. Vaccination during pregnancy transfers maternal antibodies across the placenta and can reduce pertussis among infants younger than 2 months by more than 75%. Protection against hospitalization and severe infant disease can exceed 90% in well-implemented maternal programs. Expanding pregnancy vaccination from mature markets into countries where maternal coverage remains below 50% could create a substantial additional immunization pool. Next-generation vaccine development offers another opportunity. Research programs are evaluating improved acellular formulations, additional antigens, new adjuvants, live-attenuated approaches, and technologies designed to produce longer-lasting immunity. Products capable of improving durability by even 20%–30% could reduce immunity gaps between booster doses. 

CHALLENGE

"Persistent outbreaks despite high vaccination coverage"

The Pertussis Vaccine Industry faces the challenge that outbreaks can occur even where childhood immunization coverage exceeds 90%. Pertussis transmission is influenced by waning immunity, missed boosters, population clustering, pathogen evolution, delayed diagnosis, and reduced protection several years after acellular vaccination. This creates a more complex market than diseases where a completed childhood series provides very long-lasting protection. In highly vaccinated populations, protection can progressively decline after the final childhood dose, producing susceptible adolescent and adult groups capable of transmitting infection to infants. Infants below 12 months carry disproportionate risk of hospitalization and serious complications, making protection of household contacts and pregnant women especially important. Manufacturers also face technical difficulty in developing vaccines that combine low reactogenicity with broader and longer-lasting immunity. Improving durability by 25% or more while maintaining acceptable safety and compatibility with combination vaccines remains an important development target. These challenges are shaping Pertussis Vaccine Industry Analysis, procurement planning, booster policies, and research investment.

Pertussis Vaccine Market Segmentation

The Pertussis Vaccine Market segmentation is divided by type into Acellular Vaccines and Whole-cell Vaccines and by application into 12 Months Below and 12 Months Above. Acellular vaccines account for an estimated 68% of commercially significant demand, while whole-cell vaccines represent about 32%. By application, children aged 12 months and below account for approximately 44% of dose-intensive primary immunization demand, while the 12 months above category represents about 56% because it includes later childhood doses, adolescents, adults, and maternal vaccination.

BY TYPE

Acellular Vaccines: Acellular vaccines hold an estimated 68% share of the commercially significant Pertussis Vaccine Market and are particularly important across North America, Europe, Japan, Australia, and other developed immunization systems. These vaccines contain selected purified pertussis antigens rather than entire killed bacterial cells. Common formulations contain between 1 and 5 pertussis antigens and are frequently combined with diphtheria and tetanus components. Their market position is supported by lower rates of fever and local reactions compared with traditional whole-cell formulations. In the USA, routine childhood pertussis vaccination is based on acellular DTaP products, with 5 childhood doses recommended before or during early school age. Tdap formulations extend the acellular segment into adolescents, adults, and pregnant women. Routine adolescent vaccination at 11–12 years and vaccination during every pregnancy create repeated demand beyond infancy. Pertussis Vaccine Market Insights indicate that acellular technology will remain important for manufacturers targeting high-income public procurement, private vaccination, combination products, maternal vaccination, and booster programs.

Whole-cell Vaccines: Whole-cell vaccines represent approximately 32% of Pertussis Vaccine Market demand and remain highly relevant to national immunization programs where affordability, established manufacturing capacity, and large-volume procurement are priorities. Whole-cell products use killed Bordetella pertussis organisms and have decades of clinical and programmatic use. They are commonly supplied as combination vaccines containing diphtheria and tetanus components and may be incorporated into broader pediatric combinations. Their strongest demand comes from low- and middle-income countries where public-sector procurement can involve millions of infant doses. Global three-dose diphtheria-tetanus-pertussis-containing vaccine coverage of about 84% demonstrates the scale of the addressable immunization population. Whole-cell products can produce more frequent fever, swelling, and temporary local reactions than acellular formulations, which contributed to the transition toward acellular vaccines in many high-income countries. However, cost advantages and established production infrastructure preserve substantial whole-cell demand. Pertussis Vaccine Industry Report assessments therefore identify this segment as strategically important for high-volume government tenders and broad childhood immunization programs.

BY APPLICATION

12 Months Below: Children aged 12 months and below represent approximately 44% of dose-intensive Pertussis Vaccine Market application demand because the first year of life contains multiple primary immunization appointments. Infants are also the population most vulnerable to severe pertussis complications, particularly before completing their initial vaccine series. In the USA, DTaP doses are routinely administered at approximately 2, 4, and 6 months, meaning 3 doses are scheduled during the first year. Similar three-dose primary schedules are used across many national immunization systems. Globally, approximately 84% of infants receive three doses of diphtheria-tetanus-pertussis-containing vaccine, demonstrating very high utilization within this application. The remaining 16% coverage gap represents both a public-health challenge and an opportunity for immunization expansion. 

12 Months Above: The 12 Months Above application accounts for an estimated 56% of the broader Pertussis Vaccine Market when later childhood vaccination, adolescent boosters, adult immunization, pregnancy vaccination, and selected occupational or household recommendations are combined. Children continue receiving scheduled DTaP doses after infancy, including a dose around 15–18 months and another around 4–6 years under the USA schedule. Adolescents routinely receive Tdap at approximately 11–12 years, while adults without previous Tdap vaccination may require a dose based on immunization guidance. Pregnancy provides an especially important recurring market because Tdap is recommended during every pregnancy regardless of previous vaccination status. Administration between 27 and 36 weeks maximizes passive antibody transfer to infants. Maternal vaccination can provide protection exceeding 90% against severe pertussis outcomes among very young infants. 

Pertussis Vaccine Market Regional Outlook

The Pertussis Vaccine Market shows broad regional demand because pertussis-containing vaccination is included in routine immunization programs across most countries. North America accounts for an estimated 35% share of commercially significant demand, followed by Europe at about 29%, Asia-Pacific at approximately 28%, and Middle East & Africa at nearly 8%, representing an overall 100% share. North America benefits from DTaP, Tdap, maternal, and booster programs, while Europe maintains high childhood coverage. Asia-Pacific combines very large birth cohorts with expanding immunization infrastructure. Middle East & Africa offers Pertussis Vaccine Market Opportunities through coverage improvement, public procurement, and vaccination access expansion.

NORTH AMERICA

North America holds an estimated 35% Pertussis Vaccine Market Share, supported by structured childhood immunization, adolescent boosters, maternal vaccination, and established healthcare delivery. In the USA, the childhood DTaP schedule contains 5 recommended doses, with the first 3 generally administered at 2, 4, and 6 months. Another dose is administered at 15–18 months and a fifth at 4–6 years. Adolescents generally receive Tdap at 11–12 years, while Tdap vaccination is recommended during every pregnancy. Childhood uptake for several early DTaP measures exceeds 90%, creating consistent procurement requirements. Maternal vaccination is particularly important because properly timed Tdap vaccination during pregnancy can prevent more than 75% of pertussis cases among very young infants and more than 90% of severe outcomes. Canada also maintains broad pertussis-containing childhood vaccination and booster programs, strengthening regional Pertussis Vaccine Market Growth.

EUROPE

Europe represents an estimated 29% of the Pertussis Vaccine Market, supported by national vaccination schedules, high infant immunization rates, booster programs, and growing attention toward maternal protection. Diphtheria-tetanus-pertussis-containing vaccine coverage exceeds 90% across many European countries, although vaccination schedules and booster timing differ between national systems. Acellular formulations have a strong position because numerous countries shifted from whole-cell pertussis vaccines toward lower-reactogenicity acellular products. Several European vaccination systems also recommend pertussis boosters for adolescents, adults, pregnant women, or selected close contacts of infants. Pregnancy programs are especially important because newborns cannot complete their own primary vaccine series immediately after birth. Pertussis Vaccine Market Analysis indicates that established combination-vaccine purchasing, national tender systems, surveillance programs, and booster requirements support regional demand. Coverage gaps of even 5%–10% within specific communities can create susceptible population clusters, keeping pertussis prevention important despite generally high regional vaccination levels.

ASIA-PACIFIC

Asia-Pacific accounts for approximately 28% of Pertussis Vaccine Market demand and represents one of the largest volume opportunities because the region contains major birth populations and extensive government immunization programs. Both acellular and whole-cell technologies are used, creating a diverse supplier environment. China, India, Japan, South Korea, Australia, and Southeast Asian countries contribute substantially to vaccine administration. In countries prioritizing lower procurement costs, whole-cell formulations retain an important position, while developed healthcare systems show stronger acellular vaccine penetration. Primary diphtheria-tetanus-pertussis coverage exceeds 90% in several regional markets, although coverage remains uneven between countries and population groups. Asia-Pacific Pertussis Vaccine Market Forecast opportunities are supported by domestic manufacturing expansion, combination vaccines, public immunization tenders, maternal vaccination, and improved cold-chain infrastructure. Increasing coverage from 80% to above 90% in underserved populations can materially increase dose requirements because each infant primary series requires multiple vaccine administrations.

MIDDLE EAST & AFRICA

Middle East & Africa holds an estimated 8% Pertussis Vaccine Market Share but represents a major immunization-access opportunity. Several higher-income Middle Eastern countries maintain childhood diphtheria-tetanus-pertussis coverage above 90%, whereas vaccination levels are considerably lower in some conflict-affected and resource-constrained African populations. The region therefore combines mature national programs with markets requiring significant catch-up vaccination and infrastructure expansion. Whole-cell combination vaccines remain important because cost efficiency supports high-volume public-sector purchasing. International vaccination initiatives, expanded primary healthcare, mobile immunization services, and cold-chain investment can raise coverage by 10%–20% in underserved populations. The Pertussis Vaccine Market Outlook is also influenced by rapid population growth and large annual birth cohorts. Improving access to three-dose primary vaccination remains central because incomplete immunization leaves infants exposed during the period associated with the highest risk of severe pertussis complications.

List of Key Pertussis Vaccine Market Companies

• Sanofi Pasteur
• GSK
• Mitsubishi Tanabe Pharma
• Wuhan Institute of Biological Products
• Walvax Biotechnology
• Minhai Biotechnology
• KM Biologics
• Chengdu Institute of Biological Products

Top Two Companies with Highest Share

• GSK: Estimated at approximately 27% share of the addressable branded pertussis-containing vaccine segment, supported by established pediatric and booster combination vaccines.
• Sanofi Pasteur: Estimated at approximately 24% share, supported by broad DTaP and Tdap positioning across childhood, adolescent, adult, and maternal immunization channels.

Investment Analysis and Opportunities

Investment activity in the Pertussis Vaccine Market is increasingly directed toward manufacturing capacity, combination vaccines, improved antigen technologies, maternal immunization, and longer-lasting protection. Global three-dose diphtheria-tetanus-pertussis-containing vaccine coverage is approximately 84%, leaving around 16% of infants without complete primary-series protection. Raising global completion by only 5 percentage points would translate into millions of additional children requiring multiple vaccine doses. This creates opportunities for manufacturers with scalable production, reliable cold-chain distribution, and competitive public-sector products. Asia-Pacific and parts of Africa provide particularly strong volume potential because large birth cohorts combine with vaccination coverage gaps. Investment in local fill-and-finish capacity can also reduce supply dependence and improve tender competitiveness. Acellular vaccines represent an estimated 68% of commercially significant demand, making purified-antigen manufacturing, formulation efficiency, and combination-product development important areas for capital allocation.

Another major investment opportunity is expansion beyond infant vaccination. Maternal Tdap programs can prevent more than 75% of pertussis cases among infants during their most vulnerable early period and can provide more than 90% protection against severe infant outcomes in several assessments. However, maternal uptake remains uneven, leaving substantial expansion potential. Adolescent and adult booster programs provide another recurring demand stream because immunity can decline over time. Manufacturers investing in products that improve protection duration by 20%–30% could gain strategic advantages in future procurement programs. The Pertussis Vaccine Market Research Report also identifies opportunities in next-generation adjuvants, additional pertussis antigens, live-attenuated candidates, thermostability improvements, prefilled delivery formats, and broader pediatric combinations. For B2B buyers, investment priorities increasingly include manufacturing resilience, dual sourcing, local production partnerships, and inventory planning capable of maintaining vaccination programs during unexpected outbreaks or supply disruptions.

New Products Development

New product development in the Pertussis Vaccine Market focuses heavily on improving the durability and breadth of immunity while maintaining the favorable tolerability associated with modern acellular formulations. Current acellular products commonly contain between 1 and 5 purified pertussis antigens, depending on formulation and manufacturer. Researchers are evaluating expanded antigen combinations, alternative adjuvants, improved antigen presentation, genetically modified components, and live-attenuated intranasal approaches. A next-generation product capable of increasing effective protection duration by 25% could materially reduce susceptibility between scheduled booster doses. Combination-product development is equally important because a single pediatric injection can protect against 3 or more diseases, reducing the number of separate injections and simplifying clinic logistics. 

Maternal and neonatal protection is another major development area. Pregnancy vaccination already provides more than 75% protection against pertussis among very young infants in several evaluations, demonstrating the value of antibody transfer before newborn vaccination begins. New formulations are being investigated to improve antibody quality, persistence, mucosal immunity, and protection against transmission. Developers are also studying technologies intended to generate broader immune responses than existing acellular vaccines. Manufacturing improvements remain important because reducing production losses by 10% can increase available doses without equivalent expansion of production facilities. Prefilled syringes, improved temperature stability, advanced quality monitoring, and simplified combination formulations can further improve vaccine deployment. 

Five Recent Developments

• Sanofi manufacturing expansion during 2025, vaccine manufacturing investment continued to emphasize modernization and higher production flexibility for combination and booster vaccines. Newer facilities increasingly target more than 20% improvement in manufacturing efficiency through automation, digital monitoring, and optimized filling operations, supporting reliable pertussis-containing vaccine supply.
• GSK vaccine portfolio development during 2025, development activity continued around adult, maternal, pediatric, and combination vaccination strategies. Maternal pertussis immunization remains strategically important because vaccination during pregnancy can prevent more than 75% of disease among very young infants and more than 90% of severe outcomes in several assessments.
• Chinese manufacturers expand combination-vaccine capacity during 2025, domestic manufacturers continued strengthening production capabilities for pertussis-containing pediatric vaccines. Expansion programs increasingly target production-efficiency gains above 15%, while combination products remain important for national vaccination because they reduce separate injections and improve immunization-session efficiency.
• Next-generation pertussis research advances during 2025, manufacturers and research groups continued evaluating new antigens, adjuvants, live-attenuated approaches, and improved acellular technologies. Development programs increasingly seek protection-duration improvements of 20% or more while preserving favorable safety and tolerability characteristics.
• Maternal immunization receives greater focus during 2025, vaccine strategies increasingly emphasized pregnancy vaccination and protection during the first months of life. Maternal Tdap can exceed 90% effectiveness against severe pertussis outcomes among young infants, supporting stronger integration of pregnancy immunization into preventive-care programs.

Report Coverage Of Pertussis Vaccine Market

The Pertussis Vaccine Market Report provides comprehensive coverage of vaccine types, applications, regional performance, competitive positioning, immunization patterns, product development, investment opportunities, and demand drivers. By type, the analysis evaluates Acellular Vaccines, representing an estimated 68% of commercially significant demand, and Whole-cell Vaccines, accounting for approximately 32%. Application analysis covers 12 Months Below at about 44% and 12 Months Above at approximately 56%, including childhood, adolescent, adult, booster, and maternal immunization requirements. The Pertussis Vaccine Market Analysis also evaluates global three-dose vaccination coverage of approximately 84% and the remaining 16% immunization gap influencing future public-health procurement.

Regional coverage evaluates North America at approximately 35%, Europe at 29%, Asia-Pacific at 28%, and Middle East & Africa at 8%, representing 100% of the assessed regional market. The Pertussis Vaccine Industry Report examines leading manufacturers including Sanofi Pasteur, GSK, Mitsubishi Tanabe Pharma, Wuhan Institute of Biological Products, Walvax Biotechnology, Minhai Biotechnology, KM Biologics, and Chengdu Institute of Biological Products. Pertussis Vaccine Market Insights also cover maternal vaccination, booster requirements, waning immunity, combination-vaccine development, manufacturing expansion, cold-chain needs, and next-generation technologies.